Systemic lupus erythematosus: Review of synthetic drugs

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 18, 2015, Pages 2793-2806

  Tsang A Sjoe, M W P ^a   Bultink, I E M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

azathioprine; cyclophosphamide; efficacy; glucocorticoids; hydroxychloroquine; methotrexate; mycophenolate mofetil; prednisone; synthetic drugs; systemic lupus erythematosus

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; BETA2 GLYCOPROTEIN 1; CELECOXIB; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DAPSONE; DRUG; ESSENTIAL DRUG; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; MAMMALIAN TARGET OF RAPAMYCIN; MESNA; METFORMIN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; PRASTERONE; PREDNISOLONE; PREDNISONE; RITUXIMAB; TACROLIMUS; TRANSCRIPTION FACTOR AP 1; ANTIMALARIAL AGENT; CALCINEURIN INHIBITOR; LEPROSTATIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

AGRANULOCYTOSIS; CREATININE BLOOD LEVEL; DISEASE COURSE; DISEASE EXACERBATION; DRESS SYNDROME; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HEMOLYSIS; HEMORRHAGIC CYSTITIS; HUMAN; INFECTION; INFERTILITY; KIDNEY INJURY; LEUKOPENIA; METHEMOGLOBINEMIA; NEPHROTIC SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEINURIA; RASH; RELAPSE; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SKIN MANIFESTATION; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIMALARIALS; CALCINEURIN INHIBITORS; GLUCOCORTICOIDS; HUMANS; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENTS; LEPROSTATIC AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 84952716454     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.1101448     Document Type: Review

References (121)

1. D'Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet. 2007;369:587-596.
2. Borchers AT, Keen CL, Shoenfeld Y, et al. Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. Autoimmun Rev. 2004;3:423-453.
3. Wallace DJ, Metzger AL, Klinenberg JR. NSAID usage patterns by rheumatologists in the treatment of SLE. J Rheumatol. 1989;16:557-560.
4. Karsh J, Kimberly RP, Stahl NI, et al. Comparative effects of aspirin and ibuprofen in the management of systemic lupus erythematosus. Arthritis Rheum. 1980;23:1401-1404.
5. Lander SA, Wallace DJ, Weisman MH. Celecoxib for systemic lupus erythematosus: case series and literature review of the use of NSAIDs in SLE. Lupus. 2002;11:340-347.
6. Kuznik A, Bencina M, Svajger U, et al. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol. 2011;186:4794-4804.
7. Williams HJ, Egger MJ, Singer JZ, et al. Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus. J Rheumatol. 1994;21:1457-1462.
8. Ruiz-Irastorza G, Khamashta MA. Hydroxychloroquine: the cornerstone of lupus therapy. Lupus. 2008;17:271-273.
9. Sugai DY, Gustafson CJ, De Luca JF, et al. Trends in the outpatient medication management of lupus erythematosus in the United States. J Drugs Dermatol. 2014;13:545-552.
10. Norgaard JC, Stengaard-Pedersen K, Norgaard M, et al. Antimalarials in the treatment of systemic lupus erythematosus: a registry-based cohort study in Denmark. Lupus. 2015;24:299-306.
11. Tsang-A-Sjoe MWP, Bultink IEM, Voskuyl AE. Long-term evaluation of antimalarials in a Dutch SLE cohort: intolerance and other reasons for non-use. Clin Exp Rheumatol. 2014;32:95-100.
12. Schmajuk G, Yazdany J, Trupin L, et al. Hydroxychloroquine treatment in a community-based cohort of patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2010;62:386-392.
13. Tsakonas E, Joseph L, Esdaile JM, et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus. 1998;7:80-85.
14. Costedoat-Chalumeau N, Amoura Z, et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum. 2006;54:3284-3290.
15. Costedoat-Chalumeau N, Galicier L, Aumaitre O, et al. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). Ann Rheum Dis. 2013;72:1786-1792.
16. Petri M, Purvey S, Fang H, et al. Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. Arthritis Rheum. 2012;64:4021-4028.
17. Molad Y, Gorshtein A, Wysenbeek AJ, et al. Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort. Lupus. 2002;11:356-361.
18. Fessler BJ, Alarcon GS, McGwin G Jr, et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum. 2005;52:1473-1480.
19. Andrade RM, Alarcon GS, Fernandez M, et al. Accelerated damage accrual among men with systemic lupus erythematosus: XLIV. Results from a multiethnic US cohort. Arthritis Rheum. 2007;56:622-630.
20. Mok CC, Ho CT, Wong RW, et al. Damage accrual in southern Chinese patients with systemic lupus erythematosus. J Rheumatol. 2003;30:1513-1519.
21. Akhavan PS, Su J, Lou W, et al. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus. J Rheumatol. 2013;40:831-841.
22. Pons-Estel GJ, Alarcon GS, McGwin G Jr, et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum. 2009;61:830-839.
23. Pons-Estel GJ, Alarcon GS, Burgos PI, et al. Mestizos with systemic lupus erythematosus develop renal disease early while antimalarials retard its appearance: data from a Latin American cohort. Lupus. 2013;22:899-907.
24. Janku F, McConkey DJ, Hong DS, et al. Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol. 2011;8:528-539.
25. Ruiz-Irastorza G, Ugarte A, Egurbide MV, et al. Antimalarials may influence the risk of malignancy in systemic lupus erythematosus. Ann Rheum Dis. 2007;66:815-817.
26. Ruiz-Irastorza G, Egurbide MV, Pijoan JI, et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus. 2006;15:577-583.
27. Alarcon GS, McGwin G, Bertoli AM, et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis. 2007;66:1168-1172.
28. Voss A, Laustrup H, Hjelmborg J, et al. Survival in systemic lupus erythematosus, 1995-2010. A prospective study in a Danish community. Lupus. 2014;22:1185-1191.
29. Zheng ZH, Zhang LJ, Liu WX, et al. Predictors of survival in Chinese patients with lupus nephritis. Lupus. 2012;21:1049-1056.
30. Shinjo SK, Bonfa E, Wojdyla D, et al. Antimalarial treatment may have a timedependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum. 2010;62:855-862.
31. Hernandez-Cruz B, Tapia N, Villa-Romero AR, et al. Risk factors associated with mortality in systemic lupus erythematosus. A case-control study in a tertiary care center in Mexico City. Clin Exp Rheumatol. 2001;19:395-401.
32. Petri M, Lakatta C, Magder L, et al. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med. 1994;96:254-259.
33. Tam LS, Gladman DD, Hallett DC, et al. Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol. 2000;27:2142-2145.
34. Mercer E, Rekedal L, Garg R, et al. Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals. Arthritis Res Ther. 2012;14:R135.
35. Chen Y-M, Lin C-H, Lan T-H, et al. Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: a populationbased cohort study. Rheumatology (Oxford). 2015;54:1244-1249.
36. Penn SK, Kao AH, Schott LL, et al. Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol. 2010;37:1136-1142.
37. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69:20-28.
38. Jancinova V, Nosal R, Petrikova M. On the inhibitory effect of chloroquine on blood platelet aggregation. Thromb Res. 1994;74:495-504.
39. Rand JH, Wu XX, Quinn AS, et al. Hydroxychloroquine directly reduces the binding of antiphospholipid antibodybeta2-glycoprotein I complexes to phospholipid bilayers. Blood. 2008;112:1687-1695.
40. Levy RA, Vilela VS, Cataldo MJ, et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus. 2001;10:401-404.
41. Cortes-Hernandez J, Ordi-Ros J, Paredes F, et al. Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies. Rheumatology (Oxford). 2002;41:643-650.
42. Koh JH, Ko HS, Kwok SK, et al. Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus. Lupus. 2015;24:210-217.
43. Izmirly PM, Costedoat-Chalumeau N, Pisoni C, et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent Anti-SSA/Ro associated cardiac manifestations of neonatal lupus. Circulation. 2012;126:76-82.
44. Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132:1453-1460.
45. Mosca M, Tani C, Aringer M, et al. Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice. Autoimmun Rev. 2011;10:383-388.
46. Marmor FF, Kellner U, Lai TY, et al. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophtalmology. 2011;118:415-422.
47. Ad Hoc Working Group on Steroid-Sparing Criteria in Lupus. Criteria for steroid-sparing ability of interventions in systemic lupus erythematosus: report of a consensus meeting. Arthritis Rheum. 2004;50:3427-3431.
48. Luijten RK, Fritsch-Stork RD, Bijlsma JW, et al. The use of glucocorticoids in systemic lupus erythematosus. After 60 years still more an art than science. Autoimmun Rev. 2013;12:617-628.
49. Pego-Reigosa JM, Rua-Figueroa I, Lopez-Longo FJ, et al. Analysis of disease activity and response to treatment in a large Spanish cohort of patients with systemic lupus erythematosus. Lupus. 2014;24:720-729.
50. Bruce IN, O'Keeffe AG, Farewell V, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis. 2015;74:1706-1713.
51. Gladman DD, Urowitz MB, Rahman P, et al. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol. 2003;30:1955-1959.
52. Thamer M, Hernan MA, Zhang Y, et al. Prednisone, lupus activity, and permanent organ damage. J Rheumatol. 2009;36:560-564.
53. Al Sawah S, Zhang X, Zhu B, et al. Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus-the Hopkins Lupus Cohort. Lupus Sci Med. 2015;2: e000066.
54. Stojanovich L, Stojanovich R, Kostich V, et al. Neuropsychiatric lupus favourable response to low dose i.v. cyclophosphamide and prednisolone (pilot study). Lupus. 2003;12:3-7.
55. Austin HA III, Klippel JH, Balow JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med. 1986;314:614-619.
56. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus highdose intravenous cyclophosphamide. Arthritis Rheum. 2002;46:2121-2131.
57. Houssiau FA, Vasconcelos C, D'Cruz D, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010;69:61-64.
58. ACCESS Trial Group. Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study. Arthritis Rheumatol. 2014;66:3096-3104.
59. Alchi B, Jayne D, Labopin M, et al. Autologous haematopoietic stem cell transplantation for systemic lupus erythemematosus: data from the European Group for Blood and Marrow Transplantation registry. Lupus. 2013;22:245-253.
60. Jayne D, Passweg J, Marmont A, et al. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus. 2004;13:168-176.
61. Illei G, Cervera R, Burt RK, et al. Current state and future directions of autologous haematopoietic stem cell transplantation in systemic lupus erythematosus. Ann Rheum Dis. 2011;70:2071-2074.
62. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20:1103-1112.
63. Grootscholten C, Ligtenberg G, Hagen EC, et al. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int. 2006;70:732-742.
64. Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64:1215-1226.
65. Liu Z, Zhang H, Liu Z, et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med. 2015;162:18-26.
66. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism And European Renal Association-European Dialysis and Transplant Association (EULAR/ERAEDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71:1771-1782.
67. Hahn BH, Kantor OS, Osterland CK. Azathioprine plus prednisone compared with prednisone alone in the treatment of systemic lupus erythematosus. Report of a prospective controlled trial in 24 patients. Ann Intern Med. 1975;83:597-605.
68. Oelzner P, Abendroth K, Hein G, et al. Predictors of flares and long-term outcome of systemic lupus erythematosus during combined treatment with azathioprine and low-dose prednisolone. Rheumatol Int. 1996;16:133-139.
69. Ginzler E, Sharon E, Diamond H, et al. Long-term maintenance therapy with azathioprine in systemic lupus erythematosus. Arthritis Rheum. 1975;18:27-34.
70. Griffiths B, Emery P, Ryan V, et al. The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE. Rheumatology (Oxford). 2010;49:723-732.
71. Silman AJ, Petrie J, Hazleman B, et al. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Ann Rheum Dis. 1988;47:988-992.
72. Bernatsky S, Joseph L, Boivin JF, et al. The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study. Ann Rheum Dis. 2008;67:74-79.
73. Rua-Figueroa I, Richi P, Lopez-Longo FJ, et al. Comprehensive description of clinical characteristics of a large systemic lupus erythematosus cohort from the Spanish Rheumatology Society Lupus Registry (RELESSER) with emphasis on complete versus incomplete lupus differences. Medicine (Baltimore). 2015;94:e267.
74. Tamirou F,D'CruzD, Sangle S, et al. Longterm follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann Rheum Dis. 2015 Mar 10 [Epub ahead of print], doi:10.1136/annrheumdis-2014-206897.
75. Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffues proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med. 2000;343:1156-1162.
76. Ong LM, Hooi LS, Lim TO, et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton). 2005;10:504-510.
77. Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353:2219-2228.
78. Maneiro JR, Lopez-Canoa N, Salgado E, et al. Maintenance therapy of lupus nephritis with mycophenolate or azathioprine: systematic review and metaanalysis. Rheumatology (Oxford). 2014;53:834-838.
79. Wilson EC, Jayne DR, Dellow E, et al. The cost-effectiveness of mycophenolate mofetil as firstline therapy in active lupus nephritis. Rheumatology (Oxford). 2007;46:1096-1101.
80. Karim MY, Pisoni CN, Ferro L, et al. Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy. Rheumatology (Oxford). 2005;44:1317-1321.
81. Ginzler EM, Wofsy D, Isenberg D, et al. Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. Arthritis Rheum. 2010;62:211-221.
82. Pisoni CN, Sanchez FJ, Karim Y, et al. Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients. J Rheumatol. 2005;32:1047-1052.
83. Pisoni CN, Obermoser G, Cuadrado MJ, et al. Skin manifestations of systemic lupus erythematosus refractory to multiple treatment modalities: poor results with mycophenolate mofetil. Clin Exp Rheumatol. 2005;23:393-396.
84. Gammon B, Hansen C, Costner MI. Efficacy of mycophenolate mofetil in antimalarial-resistant cutaneous lupus erythematosus. J Am Acad Dermatol. 2011;65:717-721.
85. Bultink IE, Lems WF, Kostense PJ, et al. Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum. 2005;52:2044-2050.
86. Carneiro JR, Sato EI. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. J Rheumatol. 1999;26:1275-1279.
87. Fortin PR, Abrahamowicz M, Ferland D, et al. Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebocontrolled trial. Arthritis Rheum. 2008;59:1796-1804.
88. Islam MN, Hossain M, Haq SA, et al. Efficacy and safety of methotrexate in articular and cutaneous manifestations of systemic lupus erythematosus. Int J Rheum Dis. 2012;15:62-68.
89. Sakthiswary R, Suresh E. Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy. Lupus. 2014;23:225-235.
90. Wenzel J, Brahler S, Bauer R, et al. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. Br J Dermatol. 2005;153:157-162.
91. Miyawaki S, Nishiyama S, Aita T, et al. The effect of methotrexate on improving serological abnormalities of patients with systemic lupus erythematosus. Mod Rheumatol. 2013;23:659-666.
92. Wilson K, Abeles M. A 2 year, open ended trial of methotrexate in systemic lupus erythematosus. J Rheumatol. 1994;21:1674-1677.
93. Gansauge S, Breitbart A, Rinaldi N, et al. Methotrexate in patients with moderate systemic lupus erythematosus (exclusion of renal and central nervous system disease). Ann Rheum Dis. 1997;56:382-385.
94. Kipen Y, Littlejohn GO, Morand EF. Methotrexate use in systemic lupus erythematosus. Lupus. 1997;6:385-389.
95. Rahman P, Humphrey-Murto S, Gladman DD, et al. Efficacy and tolerability of methotrexate in antimalarial resistant lupus arthritis. J Rheumatol. 1998;25:243-246.
96. Valesini G, Priori R, Francia A, et al. Central nervous system involvement in systemic lupus erythematosus: a new therapeutic approach with intrathecal dexamethasone and methotrexate. Springer Semin Immunopathol. 1994;16:313-321.
97. Tam LS, Li EK, Wong CK, et al. Doubleblind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus. Lupus. 2004;13:601-604.
98. Remer CF, Weisman MH, Wallace DJ. Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study. Lupus. 2001;10:480-483.
99. Wang HY, Cui TG, Hou FF, et al. Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study. Lupus. 2008;17:638-644.
100. Zhang FS, Nie YK, Jin XM, et al. The efficacy and safety of leflunomide therapy in lupus nephritis by repeat kidney biopsy. Rheumatol Int. 2009;29:1331-1335.
101. Tam LS, Li EK, Wong CK, et al. Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial. Ann Rheum Dis. 2006;65:417-418.
102. Gensburger D, Kawashima M, Marotte H, et al. Lupus erythematosus with leflunomide: induction or reactivation? Ann Rheum Dis. 2005;64:153-155.
103. Zavada J, Pesickova S, Rysava R, et al. Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study. Lupus. 2010;19:1281-1289.
104. Moroni G, Doria A, Mosca M, et al. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin J Am Soc Nephrol. 2006;1:925-932.
105. Austin HA III, Illei GG, Braun MJ, et al. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol. 2009;20:901-911.
106. Mok CC, Ying KY, Yim CW, et al. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. Ann Rheum Dis. 2014 Dec 30 [Epub ahead of print], doi:10.1136/ annrheumdis-2014-206456.
107. Lahita RG, Bradlow HL, Ginzler E, et al. Low plasma androgens in women with systemic lupus erythematosus. Arthritis Rheum. 1987;30:241-248.
108. Hedman M, Nilsson E, De La Torre B. Low sulpho-conjugated steroid hormone levels in systemic lupus erythematosus (SLE). Clin Exp Rheumatol. 1989;7:583-588.
109. Crosbie D, Black C, McIntyre L, et al, Dehydroepiandrosterone for systemic lupus erythematosus. Cochrane Database Syst Rev. 2007;4:CD005114.
110. Hartkamp A, Geenen R, Godaert GL, et al. Effects of dehydroepiandrosterone on fatigue and well-being in women with quiescent systemic lupus erythematosus: a randomised controlled trial. Ann Rheum Dis. 2010;69:1144-1147.
111. Nordmark G, Bengtsson C, Larsson A, et al. Effects of dehydroepiandrosterone supplement on health-related quality of life in glucocorticoid treated female patients with systemic lupus erythematosus. Autoimmunity. 2005;38:531-540.
112. Debol SM, Herron MJ, Nelson RD. Antiinflammatory action of dapsone: inhibition of neutrophil adherence is associated with inhibition of chemoattractantinduced signal transduction. J Leukoc Biol. 1997;62:827-836.
113. Lindskov R, Reymann F. Dapsone in the treatment of cutaneous lupus erythematosus. Dermatologica. 1986;172:214-217.
114. Cortes-Hernandez J, Torres-Salido M, Castro-Marrero J, et al. Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome. Br JDermatol. 2012;166:616-623.
115. Coelho A, Souto MI, Cardoso CR, et al. Long-term thalidomide use in refractory cutaneous lesions of lupus erythematosus: a 65 series of Brazilian patients. Lupus. 2005;14:434-439.
116. Perl A. mTOR activation is a biomarker and a central pathway to to autoimmune disorders, cancer, obesity, and aging. Ann N Y Acad Sci. 2015;1346:33-44.
117. Fernandez D, Bonilla E, Mirza N, et al. Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum. 2006;54:2983-2988.
118. Lai ZW, Hanczko R, Bonilla E, et al. N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blinded, placebo-controlled trial. Arthritis Rheum. 2012;64:2937-2946.
119. Garcia RJ, Francis L, Dawood M, et al. Attention deficit and hyperactivity disorder scores are elevated and respond to N-acetylcysteine treatment in patients with systemic lupus erythematosus. Arthritis Rheum. 2013;65:1313-1318.
120. Kaplan MJ. Neutrophils in the pathogenesis and manifestations of SLE. Nat Rev Rheumatol. 2011;7:691-699.
121. Wang H, Li T, Chen S, et al. NETs mitochondrial DNA and its autoantibody in systemic lupus erythematosus and a proof-of-concept trial of metformin. Arthritis Rheumatol. published online 5 Augustus 2015 2015. DOI:10.1002/ art.39269